Genomic ascertainment of PALB2 -related cancer predisposition

BACKGROUND: Cancer risk arising from a germline pathogenic PALB2 variant ascertained through a personal or family history of cancer has been well-studied. Here, we used genomic ascertainment to quantify PALB2-associated cancer risk, age-specific penetrance, all-cause and cancer-specific mortality. METHODS: We conducted a case-control study in two large population-based adult cohorts: the UK Biobank (n = 469,580) and Geisinger MyCode (n = 167,050). PALB2 P/LP heterozygotes were identified via exome sequencing and compared with non-carriers. Cancer diagnoses and vital status were obtained from linked registry and electronic health record data. We used multivariable logistic regression to estimate odds ratios for cancer outcomes and Cox proportional hazards models to estimate hazard ratios for all-cause mortality. Age-specific cumulative incidence (penetrance) was estimated using Kaplan-Meier methods. Models were adjusted for birth year, sex (when applicable), smoking status, and body mass index. RESULTS: PALB2 P/LP variant prevalence was 1:571 in UK Biobank and 1:940 in MyCode, with the higher prevalence in the UK cohort driven by the PALB2 p.Trp1038Ter founder variant. Compared with non-carriers, heterozygotes had significantly increased odds of any cancer, female breast cancer and pancreatic cancer, in both cohorts (P < 0.01). Adjusted hazard ratios for any cancer and female breast cancer ranged from 1.7 to 3.6. All-cause mortality was increased among PALB2-heterozygotes (HR 1.61-1.67), and survival after cancer diagnosis was reduced. Family history further modified cancer risk. CONCLUSIONS: Genomic ascertainment of PALB2-heterozygotes identifies elevated risk for multiple cancers and increased all-cause and cancer-specific mortality, although risks were lower than estimates from familial ascertainment.

Authors

Institutions

Publication Details

Journal
JNCI Journal of the National Cancer Institute
Published
2026-11-17
DOI
https://doi.org/10.1093/jnci/djag429
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genomic ascertainment of PALB2 -related cancer predisposition

Hyokyoung Grace Hong, J. Li, Lisa J. McReynolds, Jeremy S. Haley et al.
4 links
JNCI Journal of the National Cancer Institute
BRCA gene mutations in cancer
article

Genomic ascertainment of PALB2 -related cancer predisposition

Hyokyoung Grace Hong, J. Li, Lisa J. McReynolds, Jeremy S. Haley, Michael R. Sargen, Marc D. Tischkowitz, Douglas R. Stewart, David J. Carey, Jiang Li, Jung Gil KIM, Douglas Stewart, David J. Carey, Marc Tischkowitz, Jung Kim
article en

Abstract

BACKGROUND: Cancer risk arising from a germline pathogenic PALB2 variant ascertained through a personal or family history of cancer has been well-studied. Here, we used genomic ascertainment to quantify PALB2-associated cancer risk, age-specific penetrance, all-cause and cancer-specific mortality. METHODS: We conducted a case-control study in two large population-based adult cohorts: the UK Biobank (n = 469,580) and Geisinger MyCode (n = 167,050). PALB2 P/LP heterozygotes were identified via exome sequencing and compared with non-carriers. Cancer diagnoses and vital status were obtained from linked registry and electronic health record data. We used multivariable logistic regression to estimate odds ratios for cancer outcomes and Cox proportional hazards models to estimate hazard ratios for all-cause mortality. Age-specific cumulative incidence (penetrance) was estimated using Kaplan-Meier methods. Models were adjusted for birth year, sex (when applicable), smoking status, and body mass index. RESULTS: PALB2 P/LP variant prevalence was 1:571 in UK Biobank and 1:940 in MyCode, with the higher prevalence in the UK cohort driven by the PALB2 p.Trp1038Ter founder variant. Compared with non-carriers, heterozygotes had significantly increased odds of any cancer, female breast cancer and pancreatic cancer, in both cohorts (P < 0.01). Adjusted hazard ratios for any cancer and female breast cancer ranged from 1.7 to 3.6. All-cause mortality was increased among PALB2-heterozygotes (HR 1.61-1.67), and survival after cancer diagnosis was reduced. Family history further modified cancer risk. CONCLUSIONS: Genomic ascertainment of PALB2-heterozygotes identifies elevated risk for multiple cancers and increased all-cause and cancer-specific mortality, although risks were lower than estimates from familial ascertainment.

JNCI Journal of the National Cancer Institute
National Institute for Health and Care Research (GB), National Cancer Institute (US), Cancer Genetics (United States) (US), Geisinger Health System (US)
National Institute for Health and Care Research, National Institutes of Health, NIHR Cambridge Biomedical Research Centre, National Cancer Institute
Good health and well-being
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon